Remove Drug Delivery Systems Remove Manufacturing Remove Marketing
article thumbnail

Subcutaneous Medications and Drug Delivery Systems

Roots Analysis

Biologics constitute a majority of the top selling drugs and represent one of the fastest growing segments of the overall pharmaceutical industry. In fact, the share of biologics in the overall pharmaceutical contract manufacturing market has increased from 16% in 2006 to over 25% in 2017.

article thumbnail

Flexible grinding processes for sterile nanopharmaceutical manufacturing

Pharmaceutical Technology

Nano-based delivery systems are on the rise, as they enable manufacturers to deliver therapeutic agents to specific targeted tissue in a more controlled manner. Data indicates that the global nanopharmaceutical drugs market size reached USD 53.85 Billion in 2021 and is expected to reach USD 102.4 Billion in 2030.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Leading commercial dose (non-sterile) companies in contract marketing

Pharmaceutical Technology

Contract marketing companies support pharmaceutical companies in creating, improving, and maintaining their brand, as well as reducing risk, and ensuring better product placement in the market. Identifying the top commercial dose (non-sterile) companies in contract marketing.

Marketing 100
article thumbnail

Intranasal Therapeutics and Drug Delivery Systems: The Perfect Alternative to Conventional Route of Administration

Roots Analysis

Further, most of the funding reported by intranasal therapeutics and drug delivery systems domain were secondary offerings. Intranasal Therapeutics and Drug Delivery Systems. The intranasal therapeutics and drug delivery systems market is anticipated to grow significantly, during 2022-2035.

article thumbnail

Accelerating Oligonucleotide Demand: A Force Driving The Contract Manufacturing Market

Roots Analysis

The overall manufacturing of oligonucleotides involves the following steps. Owing to the incessant demand for oligonucleotide-based products, several small to mid-sized companies and certain pharma giants, have begun outsourcing their manufacturing operations to contract service providers. Accelerating Oligonucleotide Demand.

article thumbnail

Exosomes: A Deeper Look into Service Providers Market

Roots Analysis

Presently, outsourcing of exosome related services has become a popular practice where drug developers are actively outsourcing their operations to specialized repurposed-based service providers, which are known to have the required capabilities and expertise. Exosome Service Providers – Current Market Landscape. Web: [link].

article thumbnail

Prefilled syringes and vaccines: Optimising parenteral packaging for the next pandemic

Pharmaceutical Technology

When it comes to vaccines and other high-value biologics, it is essential that effective formulations go hand in hand with safe delivery. To boost the profitability of the drug at a later stage in its lifecycle, manufacturers may then consider changing the presentation to prefilled syringes. Lowering extractables levels .

Packaging 130